The Adjunctive Effect of a Titanium Brush in the Non-Surgical Treatment of Peri-Implantitis

NCT ID: NCT06843928

Last Updated: 2025-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-12

Study Completion Date

2026-07-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Peri-implantitis is a plaque-associated condition occurring around dental implants, characterized by inflammation in the peri-implant mucosa and loss of supporting bone. To stop this progression, mechanical debridement of biofilm and calculus is commonly used to treat peri-implant lesions as well as the use of adjunctive measures such as titanium brushes. As observed, they improved plaque removal when compared with steel curettes alone. Therefore, it is of interest to evaluate the impact of this procedure in terms of clinical, radiographic and microbiological outcomes to assess their efficacy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peri-implantitis Titanium Brush Non-surgical Submucosal Debridement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Participants will receive submucosal debridement alone

Group Type ACTIVE_COMPARATOR

Submucosal debridement

Intervention Type DEVICE

Participants will undergo non-surgical submucosal debridement alone (SD)

Submucosal debridement + titanium brushes

Intervention Type DEVICE

Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)

Test Group

Participants will receive submucosal debridement and titanium brushes

Group Type EXPERIMENTAL

Submucosal debridement

Intervention Type DEVICE

Participants will undergo non-surgical submucosal debridement alone (SD)

Submucosal debridement + titanium brushes

Intervention Type DEVICE

Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Submucosal debridement

Participants will undergo non-surgical submucosal debridement alone (SD)

Intervention Type DEVICE

Submucosal debridement + titanium brushes

Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with ≥18 years of age.
* Ability to understand all the study procedures and to comply with them along the entire study period. Ability and willingness to give written informed consent.
* An adequate level of oral hygiene (plaque index ≤ 25%) (O'Leary et al., 1972).
* Treated periodontal disease.
* Presence of at least one titanium implant with peri-implantitis \[i.e., presence of bleeding and/or suppuration on gentle probing with probing depth of ≥6 mm, and progressive bone loss. In the absence of initial radiographs, a bone level ≥2 mm apical to the most coronal part of the intrabony portion of the implant will be used as threshold of disease (Romandini et al., 2021)\].
* Horizontal and vertical peri-implant bone defects.
* Implant function time ≥ 1 year.
* Presence of ≥2mm of keratinized peri-implant mucosa.
* Screw-retained single and multiple restorations.

Exclusion Criteria

* Untreated periodontitis.
* Smokers \> 10 cigarettes per day.
* Local or systemic diseases that would interfere with routine periodontal therapy (i.e., uncontrolled diabetes mellitus, cancer, HIV, chronic high-dose steroid therapy, metabolic bone disease, radiation, immunosuppressive disease, hepatic dysfunction, immunosuppressive disease, autoimmune disease).
* Pregnant or lactating women.
* Previous surgical and non-surgical treatment of affected implants at least 12 months prior to the beginning of the study.
* Radiographic peri-implant bone loss \> two-thirds.
* Mobility of the implant.
* Known allergy or intolerance to macrolides.
* Use of systemic antibiotics during the last 3 months.
* Need of endocarditis prophylaxis.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitat Internacional de Catalunya

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Javi Vilarrasa

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitat Internacional de Catalunya

Barcelona, Catalonia, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Javi Vilarrasa

Role: CONTACT

+34 628553000

Fares Al Hajeb

Role: CONTACT

+34 696062892

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Javi Vilarrasa

Role: primary

+34 628553000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PER-ECL-2024-05

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SPiT-frequency I_Peri-implant Mucositis
NCT06737328 NOT_YET_RECRUITING NA